Hsbc Holdings PLC Purchases 30,155 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Hsbc Holdings PLC grew its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 5.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 561,289 shares of the company's stock after purchasing an additional 30,155 shares during the quarter. Hsbc Holdings PLC's holdings in Teva Pharmaceutical Industries were worth $12,374,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Robeco Institutional Asset Management B.V. grew its stake in shares of Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock valued at $10,983,000 after buying an additional 33,277 shares during the last quarter. Pinnbrook Capital Management LP purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at about $4,966,000. Asset Management One Co. Ltd. grew its position in Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after acquiring an additional 58,413 shares during the last quarter. CWA Asset Management Group LLC purchased a new position in Teva Pharmaceutical Industries in the 4th quarter worth approximately $3,340,000. Finally, Allspring Global Investments Holdings LLC lifted its position in Teva Pharmaceutical Industries by 2,018.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company's stock valued at $23,368,000 after purchasing an additional 1,045,305 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Up 3.8 %

Shares of NYSE:TEVA traded up $0.60 during midday trading on Friday, reaching $16.22. The company's stock had a trading volume of 11,919,719 shares, compared to its average volume of 9,977,348. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The firm has a 50 day moving average of $15.11 and a 200-day moving average of $17.49. The firm has a market capitalization of $18.39 billion, a P/E ratio of -11.19, a PEG ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analysts Set New Price Targets

TEVA has been the topic of several analyst reports. StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday, April 23rd. UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Piper Sandler increased their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Finally, Bank of America dropped their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.